Polymeric photothermal agents for cancer therapy: recent progress and clinical potential,Journal of Materials Chemistry B

当前位置： X-MOL 学术 › J. Mater. Chem. B › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Polymeric photothermal agents for cancer therapy: recent progress and clinical potential
Journal of Materials Chemistry B ( IF 6.1 ) Pub Date : 2020-12-18 , DOI: 10.1039/d0tb02659j
Chang Du _{1,

2,

3,

4,

5} , Xingjie Wu _{6,

7,

8,

9} , Meng He _{1,

2,

3,

4,

5} , Yongming Zhang _{1,

2,

3,

4,

5} , Rong Zhang _{4,

10,

11,

12,

13} , Chang-Ming Dong _{1,

2,

3,

4,

5}

Affiliation

Over the past decades, near infrared light (NIR)-sensitive photothermal agents (PTAs) that can efficiently absorb light and generate heat have been investigated worldwide for cancer photothermal therapy (PTT) and the combination treatments, which have some peculiar advantages including spatiotemporal targeting, the ability-to-reverse multidrug resistance, the immunity-stimulating function, and the synergistic effect in combination treatments. In this review, we first focus on emerging melanin-like polymers and coordination polyphenol polymer-based PTAs that hold transition potential because of their facile synthesis and good biocompatibility/biodegradability. We briefly introduce polymeric PTAs for emerging NIR-II (1000–1700 nm) PTT in deep tumors to overcome shallow penetration depth and threshold irradiation intensity of NIR-I (700–900 nm). Then we discuss polymeric PTAs for combination PTT treatments with photodynamic therapy (PDT), ferroptosis therapy (ferrotherapy), and immunotherapy, which are intensively studied for achieving anticancer synergistic effects. Finally, we discuss those polymeric PTAs for reversing cancer multidrug resistance and for mild/low-temperature PTT (43 °C ≤ T < 50 °C) in contrast to conventional high-temperature PTT (>50 °C). The polymeric PTA-based PTT and the combination treatments are still being developed in the early stage and need much more effort before potential clinical transitions and applications.

中文翻译：

高分子光热剂用于癌症治疗：最新进展和临床潜力

在过去的几十年中，针对癌症光热疗法（PTT）和联合疗法，已在全球范围内研究了可以有效吸收光并产生热量的近红外光（NIR）敏感的光热剂（PTA），它们具有一些独特的优势，包括时空靶向，逆转多重耐药性，增强免疫力的功能以及联合治疗的协同作用。在这篇综述中，我们首先关注新兴的类黑色素聚合物和基于配位多酚聚合物的PTA，它们由于其合成简便且具有良好的生物相容性/生物降解性而具有过渡潜力。我们简要介绍了用于深部肿瘤中新兴NIR-II（1000-1700 nm）PTT的聚合PTA，以克服浅穿透深度和NIR-1（700-900 nm）的阈值照射强度。然后，我们讨论了将PTT与光动力疗法（PDT），肥大症疗法（ferrotherapy）和免疫疗法联合使用的聚合PTA，它们已得到深入研究以实现抗癌协同作用。最后，我们讨论了用于逆转癌症多药耐药性和温和/低温PTT（43°C≤T <50°C）与常规高温PTT（> 50°C）相反。聚合的基于PTA的PTT及其联合治疗仍在早期开发中，在潜在的临床过渡和应用之前需要付出更多的努力。

更新日期：2021-01-11

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11